Amneal Pharmaceuticals (AMRX) and Metsera have entered into a collaboration agreement to enable the efficient development and large-scale supply of a portfolio of new weight loss medicines globally. Amneal will serve as Metsera's preferred supply partner for developed markets, including the United States and Europe. Amneal will also be granted a license to commercialize Metsera's products in select emerging markets, including India and certain countries in Southeast Asia, Africa and the Middle East.
Amneal said it will construct two new greenfield manufacturing facilities in India, one for peptide synthesis and one for sterile fill-finish manufacturing. The new site is expected to break ground later in the current year, with a total net cost to Amneal of between $150 million and $200 million over the next four to five years.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.